We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

131 hedge funds and large institutions have $84.1M invested in ImmunityBio in 2023 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 11

12% more funds holding

Funds holding: 117 → 131 (+14)

10% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 30

4% less call options, than puts

Call options by funds: $4.51M | Put options by funds: $4.7M

1.5% less ownership

Funds ownership: 8.97% → 7.47% (-1.5%)

23% less capital invested

Capital invested by funds: $109M → $84.1M (-$24.6M)

Holders
131
Holders Change
+14
Holders Change %
+11.97%
% of All Funds
2.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
33
Reduced
30
Closed
11
Calls
$4.51M
Puts
$4.7M
Net Calls
-$190K
Net Calls Change
-$2.05M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$8.72M
2
AC
Armistice Capital
New York
+$6.98M
3
BlackRock
BlackRock
New York
+$2.64M
4
CS
Credit Suisse
Switzerland
+$1.04M
5
Group One Trading
Group One Trading
Illinois
+$897K

Top Sellers

1
DFCM
Dark Forest Capital Management
Puerto Rico
-$566K
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$537K
3
Jane Street
Jane Street
New York
-$295K
4
National Bank of Canada
National Bank of Canada
Quebec, Canada
-$193K
5
State Street
State Street
Massachusetts
-$116K
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
101
PNC Financial Services Group
Pennsylvania
$16.9K -$20.3K -10,100 -50%
GC
102
Grimes & Company
Massachusetts
$16.9K – – –
Simplex Trading
103
Simplex Trading
Illinois
$15K +$17.8K +8,883 New
TRCT
104
Tower Research Capital (TRC)
New York
$11.1K -$14.7K -7,320 -53%
MLICM
105
Metropolitan Life Insurance Company (MetLife)
New York
$10.2K – – –
Citigroup
106
Citigroup
New York
$10.2K -$75.3K -37,482 -86%
Lazard Asset Management
107
Lazard Asset Management
New York
$10K +$538 +268 +5%
Russell Investments Group
108
Russell Investments Group
United Kingdom
$4.91K – – –
IFAM
109
Institutional & Family Asset Management
Colorado
$3.38K – – –
QC
110
Quent Capital
New York
$3.09K +$2.79K +1,392 +319%
Daiwa Securities Group
111
Daiwa Securities Group
Japan
$3K – – –
WOC
112
West Oak Capital
California
$3K – – –
US Bancorp
113
US Bancorp
Minnesota
$2.89K – – –
PA
114
Parallel Advisors
California
$1.69K +$2.01K +1,000 New
GRP
115
Global Retirement Partners
California
$1.29K – – –
AF
116
Advisornet Financial
Minnesota
$1.27K – – –
AAP
117
Arax Advisory Partners
Colorado
$1.01K – – –
BFEC
118
Benjamin F. Edwards & Company
Missouri
$1K – – –
CG
119
Cutler Group
California
$1K – – –
AW
120
Avion Wealth
Texas
$1K +$1.4K +696 New
WWM
121
Wolff Wiese Magana
California
$845 +$1K +500 New
ATC
122
Adirondack Trust Company
New York
$760 – – –
CTA
123
Colonial Trust Advisors
South Carolina
$718 – – –
SWM
124
Spire Wealth Management
Virginia
$713 – – –
SPIA
125
Steward Partners Investment Advisory
New York
$676 – – –
2 3 4
5
6

IBRX Hedge Fund Activity: Q3 2023 in Review

131 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2023, worth a combined $84.1M — down 23% from $109M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new IBRX positions and 11 closed out — a net gain of 18 holders — while 33 added to existing stakes and 30 trimmed.

The largest buyer was Vanguard Group, adding an estimated $8.72M. The largest seller was Dark Forest Capital Management, exiting entirely with an estimated $566K sold.

  • 131 institutional investors held ImmunityBio (IBRX) as of Q3 2023, up from 117 in Q2 2023.
  • Funds reported $84.1M of ImmunityBio stock for Q3 2023, down 23% quarter-over-quarter.
  • 29 funds opened new ImmunityBio positions in Q3 2023 and 11 closed out, a net change of +18 holders.
  • The largest ImmunityBio buyer in Q3 2023 was Vanguard Group, an estimated $8.72M added.
  • The largest ImmunityBio seller in Q3 2023 was Dark Forest Capital Management, an estimated $566K sold.

Based on aggregated 13F filings for Q3 2023.